Alnuside B

Alnuside B

SCHEMBL22796510

O=C(CCc1ccc(O)cc1)CC(CCc1ccc(O)c(O)c1)O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 4/20 0.49
▸ PPARD Q03181 4/20 0.49
▸ PPARA Q07869 4/20 0.49
▸ TYR P14679 4/20 0.45
▸ IAPP P10997 2/20 0.39
▸ SYNJ2 O15056 2/20 0.38
▸ POLB P06746 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ ALPL P05186 1/20 0.38
▸ ALPI P09923 1/20 0.38
▸ ALPG P10696 1/20 0.38
▸ PABPC1 P11940 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ GALK1 P51570 1/20 0.38
▸ CASP7 P55210 1/20 0.38
▸ CASP6 P55212 1/20 0.38
▸ MCL1 Q07820 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alnuside B SCHEMBL12672476 1.00 PPARG (0.49) PPARGPPARDPPARATYRIAPP
Oregonin SCHEMBL29389089 0.96 PPARG (0.46) PPARGPPARDPPARATYRIAPP
Oregonin SCHEMBL12659728 0.96 PPARG (0.46) PPARGPPARDPPARATYRIAPP
SCHEMBL22796348 0.86 PPARG (0.40) PPARGPPARDPPARATYRIAPP
SCHEMBL12659725 0.85 PPARG (0.40) PPARGPPARDPPARATYRIAPP
SCHEMBL22796193 0.83 PPARG (0.42) PPARGPPARDPPARATYRIAPP
SCHEMBL14877642 0.81 PRKCA (0.40) PPARGPPARDPPARAHSD17B10CYP3A4
SCHEMBL22796194 0.80 PPARG (0.40) PPARGPPARDPPARATYRIAPP
SCHEMBL22795998 0.80 TYR (0.39) TYRSYNJ2POLBGAAKDM4E
SCHEMBL12659733 0.79 PPARG (0.49) PPARGPPARDPPARATYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200392223-A1 IL-17A ACTIVITY INHIBITOR AND USE THEREOF TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2020-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392223-A1 IL-17A ACTIVITY INHIBITOR AND USE THEREOF IL17A, IL23R, IL15RA PPARG 1058/4885PPARD 2704/4885PPARA 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback